Total amount: € 0,00
HOW TO ORDER
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
A Journal on Dermatology and Sexually Transmitted Diseases
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Giornale Italiano di Dermatologia e Venereologia 1999 February;134(1):61-5
Efficacy and safety of the topical formulation of fluconazole 0.5% (gel containing an emulsion oil/water o/w) in the treatment of dermatomycoses with localized lesions: Results of a multicenter, open, non comparative study
Aste N. 1, Baldari U. 2, Bellini M. 3, Biggio P. 1, Pinna A. L. 1, Pau M. 1, Pavone P. S. 4, Righini M. G. 2, Vallecchi C. 3
1 Università degli Studi - Cagliari, Clinica Dermatologica;
2 Ospedale «G. B. Morgagni» - Forlì, Divisione di Dermatologia;
3 Università degli Studi - Firenze, Clinica Dermatologica;
4 Ospedale Generale di Zona - Menaggio (Como), Ambulatorio di Dermatologia
Efficacy and safety of the topical formulation of fluconazole 0.5% (gel containing an emulsion oil/water o/w) in the treatment of dermatomycoses with localized lesions: Results of a multicenter, open, non comparative study.
Background. Dermatophytoses are a group of diseases caused by keratinophilic mycetes involving the skin and its adnexa. At present, there is a wide range of antimycotic drugs which may be used by topical and systemic route with very good results and mild side-effects.
Methods. Seventy-one patients, 37 males and 34 females, age range 6-81 years, with Tinea corporis, Tinea cruris, Tinea pedis from dermatophytes or candida were treated with topical fluconazole 0.5%. The drug was applied once daily for an average period of 21±6 days.
Results. Fifty-seven patients completed the treatment and at the last follow-up 94% of them was completely cured and 6% improved. The therapeutic efficacy of topical fluconazole 0.5% resulted almost equivalent in the 3 groups: 96% of cure in patients with T. pedis, 93% in patients with T. corporis and 100% in those with T. cruris. The tolerability, both general and local, was good in 97.2% and 93% of cases, respectively. In only two cases mild and transient side effects occurred.
Conclusions. These results confirm that fluconazole, also in this new topical formulation 0.5%, is an innovative molecule, with a great antifungal potency and an excellent local tolerability.